Although outcomes have improved, children with high-risk neuroblastoma continue to face high mortality1,2
OS, overall survival.
Relapse prevention is key to improving pediatric patients' chances of survival
The addition of maintenance therapy could offer your patients an additional layer of protection against relapse. When determining if maintenance therapy is right for your patient, consider these key objectives:
- Aligns with desired treatment goals for the patient
- Possesses an established and well tolerated safety profile
- Allows for normal or near-normal resumption of a patient’s life
References
1. Sholler GLS, Ferguson W, Bergendahl G, et al. Maintenance DFMO increases survival in high risk neuroblastoma. Sci Rep. 2018;8(1):14445. doi:10.1038/s41598-018-32659-w
2. Shohet JM, Lowas SR, Nuchtern JG. Treatment and prognosis of neuroblastoma. Wolters Kluwer. UpToDate.com. Accessed December 15, 2023. Available at: https://www.uptodate.com/contents/treatment-and-prognosis-of-neuroblastoma
3. Batth IS, Dao L, Satelli A, et al. Cell surface vimentin positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of post-remission neuroblastoma patients. Int J Cancer. 2020;147(12):3550-3559. doi:10.1002/ijc.33140
4. London WB, Bagatell R, Weigel BJ, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-4923
5. Medicine.net. Life Expectancy of Neuroblastoma: Survival Rate & Prognosis. Accessed December 15, 2023. Available at: https://www.medicinenet.com/life_expectancy_of_a_child_with_neuroblastoma/article.html